1h Free Analyst Time
The latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis - Drugs In Development, 2022, provides an overview of the Osteoarthritis (Musculoskeletal Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Osteoarthritis (OA) is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms of osteoarthritis include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation. Risk factors include older age, joint injuries and obesity. Treatment includes surgery, medications like non-steroidal anti-inflammatory drugs (NSAIDs) and exercise.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Osteoarthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Osteoarthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 13, 39, 27, 2, 5, 80, 23 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 2, 9 and 7 molecules, respectively.
Osteoarthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Osteoarthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteoarthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteoarthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis (Musculoskeletal Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteoarthritis (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteoarthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionReport CoverageOsteoarthritis - OverviewOsteoarthritis - Companies Involved in Therapeutics DevelopmentOsteoarthritis - Drug ProfilesOsteoarthritis - Dormant ProjectsOsteoarthritis - Discontinued ProductsOsteoarthritis - Product Development MilestonesAppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact the Analyst
Osteoarthritis - Therapeutics Development
Osteoarthritis - Therapeutics Assessment
Featured News & Press Releases
Feb 08, 2022: Enveric Biosciences announces successful synthesis and filing of provisional patent for EV-104a - Cannabinoid + Celecoxib Conjugate
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 20MED Therapeutics BV
- 4P-Pharma SAS
- Abiogen Pharma SpA
- Achelios Therapeutics Inc
- Aclaris Therapeutics Inc
- Adare Pharma Solutions
- AfaSci Inc
- Ageless Biotech Inc
- Akaal Pharma Pty Ltd
- Akan Biosciences LLC
- AKL Research and Development Ltd
- Algomedix Inc
- Amgen Inc
- Amplicore Inc
- Amzell BV
- Aprogen Inc
- AskAt Inc
- Asta Pharmaceuticals Co Ltd
- Atlanthera
- Aurealis Pharma AG
- Axsome Therapeutics Inc
- Bioiberica SAU
- BioIntegrate Inc
- BioNet Pharma GmbH
- Bioorg3.14 LLC
- Biosplice Therapeutics Inc
- BioStem Technologies Inc
- Bioventus Inc
- BRIM Biotechnology Inc
- Buzzz Pharmaceuticals Ltd
- Caliway Biopharmaceutics Co Ltd
- CAR-T (Shanghai) Biotechnology Co Ltd
- Cartesian Therapeutics Inc
- CarthroniX Inc
- Cartilagen Inc
- Causeway Therapeutics Ltd
- Cellatoz Therapeutics Inc
- Cellics Therapeutics Inc
- CELLnLIFE Inc
- Cells for Cells SA
- CellTex Therapeutics Corp
- Cellular Biomedicine Group Inc
- Chondrogenix Ltd
- Cmxtwenty
- Cocoon Biotech, Inc.
- Corestem Inc
- CrystalGenomics Inc
- Cynata Therapeutics Ltd
- Cytonics Corp
- Cytopeutics Pte Ltd
- Daewoong Pharmaceutical Co Ltd
- Dianomi Therapeutics Inc
- DNX Biopharmaceuticals Inc
- Dongkook Pharmaceutical Co Ltd
- Eli Lilly and Co
- Ensol Biosciences Inc
- Enveric Biosciences Inc
- Epione Therapeutics BV
- Eternity Bioscience Inc
- Evgen Pharma Plc
- Exostemtech Co Ltd
- Flexion Therapeutics Inc
- Genascence Corp
- Genequine Biotherapeutics GmbH
- General Regeneratives Shanghai Ltd
- General Therapeutics Inc
- GlaxoSmithKline Plc
- GPN Therapeutics Inc
- Guangzhou Saliai Stemcell Science and Technology Co Ltd
- Gwoxi Stem Cell Applied Technology Co Ltd
- Haplnscience Inc
- Hisamitsu Pharmaceutical Co Inc
- Histogen Inc
- Hope Biosciences LLC
- Huaxia Source Cell Engineering Group Co Ltd
- iCELL Biotechnology Co Ltd
- ICM Co Ltd
- Immetas Therapeutics Inc
- ImmuneCyte Inc
- ImmunoForge Co Ltd
- Inception Therapeutics Inc
- International Stem Cell Corp
- Johnson & Johnson
- Juniper Biologics Pte Ltd
- Juvena Therapeutics Inc
- Kaken Pharmaceutical Co Ltd
- Kangstem Biotech Co Ltd
- Kolon TissueGene Inc
- Kukje Pharmaceutical Industry Co Ltd
- Levolta Pharmaceuticals Inc
- LG Chem Ltd
- Likarda LLC
- Link Biologics Ltd
- Link Health Group
- Lubris Biopharma
- Luye Pharma Group Ltd
- Magellan Biologicals Pty Ltd
- MDimune Inc
- Mecox Cure Med Co Ltd
- Medicrinia Co Ltd
- MediPost Co Ltd
- Medivir AB
- MeiraGTx Holdings Plc
- Meluha Life Sciences Sdn Bhd
- Merck KGaA
- Meridigen Biotech Co Ltd
- Mesoblast Ltd
- MetrioPharm AG
- MiMedx Group Inc
- Mor Research Applications Ltd
- Nanode Therapeutics Inc
- NeuroBo Pharmaceuticals Inc
- New York R&D Center for Translational Medicine and Therapeutics Inc
- Nexbiome Therapeutics
- Nordic Bioscience AS
- Novartis AG
- Novo Nordisk AS
- Orbsen Therapeutics Ltd
- Organicell Regenerative Medicine Inc
- Organogenesis Holdings Inc
- OrthoTrophix Inc
- Oxacell AG
- Paradigm Biopharmaceuticals Ltd
- Paras Biopharmaceuticals Finland Oy
- Parnia Stem Cell Knowledge-Based Co
- Peptinov SAS
- Personalized Stem Cells Inc
- PersonGen BioTherapeutics (Suzhou) Co Ltd
- Pfizer Inc
- PhytoHealth Corp
- Plakous Therapeutics Inc
- PlateletBio
- PMG PHARM Co Ltd
- PrimeGen Global Inc
- PrimRNA Inc
- Progenitor Therapeutics Ltd
- ProteoThera Inc
- Regeneus Ltd
- Regenosine Inc
- Regulaxis SAS
- Remedium Bio Inc
- ReqMed Co Ltd
- Ribomic Inc
- Rottapharm Biotech Srl
- Runjia (Suzhou) Pharmaceutical Technology Co Ltd
- Sclnow Biotechnology Co Ltd
- Seikagaku Corp
- Serene LLC
- Shandong Boan Biotechnology Co Ltd
- Shionogi & Co Ltd
- Simcere Pharmaceutical Group Ltd
- SL Bigen Co Ltd
- Steminent Biotherapeutics Inc
- Stempeutics Research Pvt Ltd
- Synartro AB
- Synerkine Pharma BV
- Synokem Pharmaceuticals Ltd
- Taiwan Bio Therapeutics Co Ltd
- Techfields Pharma Co Ltd
- TheraBioPharma Inc
- Traverse Biosciences Inc
- Tremeau Pharmaceuticals Inc
- Trialspark Inc
- Turn Biotechnologies Inc
- Unicocell Biomed Co Ltd
- Vitro Diagnostics Inc
- WEX Pharmaceuticals Inc
- WNT Scientific LLC
- Xalud Therapeutics Inc
- Xintela AB
- Yooyoung Pharm Co Ltd
- Zhejiang Yatai Pharmaceutical Co Ltd
- Zimmer Biomet Holdings Inc